Solid Biosciences Announces Collaboration With Mayo Clinic To Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
Solid Biosciences Inc., which acquired UF Startup AavantiBio, has partnered with Mayo Clinic to advance an AAV gene therapy platform for next-generation treatments targeting genetic cardiomyopathies and channelopathies linked to sudden cardiac death.
Kriya Announces Publication of Preclinical Data for Its Investigational AAV-FGF21 Gene Therapy Demonstrating Durable Reversal of Liver Fibrosis
UF Startup Kriya Therapeutics, a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, announced the publication of preclinical data for its investigational AAV-FGF21 gene therapy.
Solid Biosciences Shares Updates on Inspire Duchenne Clinical Trial of SGT-003
Solid Biosciences, a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases that acquired UF startup AavantiBio, shared updates on the INSPIRE DUCHENNE clinical trial for their next-generation AAV micro-dystrophin gene therapy candidate, SGT-003, for the treatment of Duchenne.
Kriya Appoints Scientific Co-Founder J. Fraser Wright, Ph.D., as Chief Gene Therapy Officer
UF startup Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, announced the appointment of J. Fraser Wright, Ph.D., to the position of chief gene therapy officer.
